Stem cell transplant: An experience from eastern India

Abstract

Background: Hematopoietic stem cell transplant using human leukocyte antigen (HLA)-matched sibling or unrelated bone marrow, or related or unrelated cord blood has been performed successfully to treat patients with different types of hematological malignancies, genetic disorders and hereditary immune deficiencies. Since 1983, stem cell transplantation has been carried out in different institutes of India. But, till then, no transplantation was performed in eastern India. Materials and Methods: Our present study is reporting for the first time stem cell transplantation in eastern India. From August 2000 to June 2011 (with a 3-year gap for up-gradation), we have performed a total of 22 transplants. Thirteen patients (M:F:9:4) with indications of aplastic anemia, thalassaemia, acute myeloid leukemia and chronic myeloid leukemia underwent allogenic transplant, whereas autologous transplant was performed for nine patients (M:F:2:1) of multiple myeloma, Hodgkin′s and non-Hodgkin′s lymphoma and neuroblastoma. The median age of the patients was 19.6 years, with a range of 5 years 8 months to 52 years. Fourteen patients received myeloablative conditioning regime whereas eight patients received immunosuppressive and less myeloablative protocol. Sources of stem cells in case of allogenic transplant are bone marrow and related or unrelated umbilical cord blood and in case of autologous transplant, these are peripheral blood stem cells or self-bone marrow. Standard prophylactic medication was followed prior to transplants. Results: A disease-free survival of 68.18% and overall survival of 86.3% were seen at the median follow-up period of 4.6 years. Common post-transplant complications were mucositis, infection, venoocclusive disease, graft versus host disease, hemorrhagic cystitis, etc. Conclusion: The use of cord blood as a source of stem cells has been proved inferior as compared with the bone marrow stem cell source in cases of thalassaemia in our institute and thus is not recommended for thalassaemia. But, it has been proved to be a very useful and effective stem cell source (both related and unrelated cord blood) in cases of aplastic anemia and other immunological disorders.

Keywords

Aplastic anemia - bone marrow transplantation - cord blood transplantation - eastern Indian data - stem cell transplantation - thalassaemia

Publication History

Article published online:
20 July 2021

• References

• 1 Chandy M. Stem cell transplantation in India. Bone Marrow Transplant 2008;42:81-4.
• 2 Kumar R. Stem cell transplantation: Indian Perspective. J Ind Acad Clinic Med 2002;3:182-8.
• 3 Saikia TK, Advani SH, Gopal R, Nair CN, Dinsha KA, Kurkure PA, et al. Preliminary experience with allogenic bone marrow transplantation in haematological disorders in India. J Assoc Physic Ind 1990;38:332-4.
• 4 Chandy M, Srivastava A, Dennison D, Mathews V, George B. Allogenic bone marrow transplantation in the developing world: Experience from a centre in India. Bone Marrow Transplant 2001;27:785-90.
• 5 Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Wernet P, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97:2962-70.
• 6 Barker JN, Davies MS, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: Results of a matched pair analysis. Blood 2001;97:2957-61.
• 7 Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337:373-81.
• 8 Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental -blood transplants from unrelated donor. N Engl J Med 1998;339:1565-77.
• 9 Wagner JE, DeFor T, Rubinstein P, Kurtzberg J. Transplantation of unrelated donor umbilical cord blood (UCB): Outcomes and analysis of risk factors. Blood 1997;90:398a.
• 10 Locatelli F, Rocha V, Chastang C, Arcese W, Michel G, Abecasis M, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord- Cord Blood Transplant Group. Blood 1999;93:3662-71.
• 11 Laughlin MJ, Barker J, Bambach B, Koc ON , Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344:1815-22.
• 12 Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogenic sibling umbilical cord- blood transplantation in children with malignant and non-malignant disease. Lancet 1995;346:214-9.
• 13 Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NK, et al. Successful transplantation of HLA-matched and HLA mismatched umbilical cord blood from unrelated donors: Analysis of engraftment and acute graft versus- host disease. Blood 1996;88:795-802.
• 14 Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-66.
• 15 Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Graft-versus-host disease in children who have received a cord blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med 2000;342:1846-54.
• 16 Sumi M, Shimizu I, Sato K, Ueki T, Akahane D, Ueno M, et al. Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation. Int J Hematol 2010;92:744-50.
• 17 Narimatsu H, Kami M, Miyakoshi S, Murashige N, Yuji K, Hamaki T, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol 2006;132:36-41.
• 18 Wagnor JE, Barker JN, Defor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-8.